MedTrace Logo

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

NCT04392479 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2023-10-23

No results posted yet for this study

Summary

Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.

Conditions

  • Cancer Colorectal
  • Metastasis

Interventions

DRUG

Aflibercept-FOLFIRI

Aflibercept-FOLFIRI

DRUG

Aflibercept-mFOLFIRI3

Aflibercept-mFOLFIRI3

Sponsors & Collaborators

  • Fondation ARCAD

    collaborator OTHER

  • Hôpital Franco-Britannique-Fondation Cognacq-Jay

    lead OTHER

Principal Investigators

  • Benoist CHIBAUDEL, MD · Franco-British Hospital GCS IHFB Cognacq-Jay

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2023-06-15
Completion
2024-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392479 on ClinicalTrials.gov